STOCK TITAN

Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Glaukos Corporation (NYSE: GKOS) announces its third quarter 2022 financial results will be released after market close on November 2, 2022. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET) for management to discuss the results. The company focuses on novel therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012. A replay of the call will be available on Glaukos' website post-event.

Positive
  • None.
Negative
  • None.

Conference Call and Webcast Scheduled for 1:30 p.m. PT

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release third quarter 2022 financial results after the market close on Wednesday, November 2, 2022. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on November 2, 2022.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company’s website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012, and continues to develop a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations. Products or product candidates for each of these platforms are designed to advance the standard of care through better treatment options across the areas of glaucoma, corneal disorders and retinal diseases.

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

clewis@glaukos.com

Source: Glaukos Corporation

FAQ

When will Glaukos report its third quarter 2022 earnings?

Glaukos will report its third quarter 2022 financial results after market close on November 2, 2022.

What time is the Glaukos conference call for Q3 2022 results?

The conference call is scheduled for 1:30 p.m. PT (4:30 p.m. ET) on November 2, 2022.

How can I access the Glaukos Q3 2022 earnings webcast?

The webcast can be accessed through Glaukos' investor relations website.

What is Glaukos Corporation's focus?

Glaukos focuses on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases.

Glaukos Corporation

NYSE:GKOS

GKOS Rankings

GKOS Latest News

GKOS Stock Data

7.93B
53.37M
3.19%
101.17%
5.1%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
ALISO VIEJO